BioMimetic completes patient enrollment for product trial

01/9/2009 | American City Business Journals

BioMimetic Therapeutics said it completed the enrollment of 436 patients in a pivotal clinical trial aimed at testing the safety and efficacy of its Augment Bone Graft in treating foot and ankle fusions against the autograft, the standard device used for such procedures. The company also received a patent term extension from the U.S. Patent and Trademark Office for its Augment product line.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI